Announced
Completed
Section 32 led a $120m Series B round in BigHat Biosciences.
Synopsis
Section 32, a venture capital fund, led a $120m Series B round in BigHat Biosciences, a biotechnology company, with participation from Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, Andreessen Horowitz, 8VC, and AME Cloud Ventures.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Claim DealAll rights reserved. Copyright © 2025 Datasite